吉西他滨联合卡铂双周方案治疗晚期非小细胞肺癌临床观察  

Clinical observation of bi-weeks' gemcitabine combined with carboplatin in the treatment of advanced non-small cell lung cancer

作　　者：吕维泽[1] 林忠[1] 彭培建[1] 陈佳群[1] 肖妹[1] 

机构地区：[1]中山大学附属第五医院化疗科,广东珠海519000

出　　处：《海南医学》2009年第2期12-13,共2页Hainan Medical Journal

摘　　要：目的观察吉西他滨联合卡铂组成的双周方案治疗晚期非小细胞肺癌(NSCLC)的疗效与安全性。方法采用吉西他滨联合卡铂双周方案治疗晚期NSCLC 32例。吉西他滨1250mg/m2,第1、15d静滴30min;卡铂按AUC=5计算,第1、15d各静滴一半,28d为1个周期,每例至少治疗2个周期。结果近期疗效完全缓解(CR)0例,部分缓解(PR)11例,稳定(SD)13例,进展(PD)8例,总有效率34.4%,随访全部32例病例,中位生存期为9.5个月,1年生存率43.8%(14/32)。最常见毒副反应为骨髓抑制,III度白细胞抑制为11.1%,没有IV度白细胞抑制,没有III-IV度血小板抑制,其他毒副反应轻微,均可耐受。结论吉西他滨联合卡铂双周方案治疗晚期NSCLC耐受性好,且有较好的疗效,值得临床进一步研究。Objective To study the efficacy and toxicities of bi - weeks＇ gemcitabine combined with carboplatin in the treatment of advanced non - small cell lung cancer （ NSCLC）. Methods 32 cases of advanced NSCLC were treated by bi -weeks＇ gemcitabine combined with carboplatin： Gemcitabine 1250 mg/m^2 iv - drop on day 1 , 15, carboplatin AUC 5 iv - drop half on day 1 and the rest on day 15. The chemotherapy was repeated every 28 days, with at least 2 cycles. Results 32 patients could be evaluated,CR,PR,SD,PD were observed in 0, 11, 13 and 8 cases. The response rate was 34.4%, the median survival time was 9.5 months, the 1 -year survival rate was 43.8%, the main toxicity was hematological toxicity （Grade Ⅲ leukopenia 11.1% ,no grade Ⅳleukopenia was seen, no grade Ⅲ- Ⅳ thromboeytopenia was seen）. Conclusion Bi - weeks＇ gemeitabine combined with carboplatin is well - tolerated and effective in the treatment of advanced NSCLC. The further study is worth to do.

关 键 词：非小细胞肺癌 吉西他滨 卡铂 化疗 

分 类 号：R734.2[医药卫生—肿瘤]